Disney Illusion Island Now Available on Nintendo Switch™
28.7.2023 15:00:00 EEST | Business Wire | Press release
Today, Disney Games, in collaboration with developer Dlala Studios, launch Disney Illusion Island globally, a local cooperative 2D platform adventure video game for up to four players, exclusively for Nintendo Switch™.
Experience a brand-new adventure as players join Mickey Mouse, Minnie Mouse, Donald Duck and Goofy on a whimsical journey through the island of Monoth. Explore this beautiful yet mysterious world to recover the three magical Tomes – powerful books used to protect the island. Disney Illusion Island gives players the chance to be a part of an authentic Mickey & Friends adventure with an original story, stunning hand-drawn animation, and an original fully orchestrated score by Ivor Novello and BAFTA-nominated composer Dave Housden.
Watch the Disney Illusion Island Launch Trailer Here.
“Disney Illusion Island marks Mickey Mouse’s return to video games and we’re honored to bring this one-of-a-kind adventure to the Nintendo Switch,” said Luigi Priore, VP, Disney, Pixar and 20th Century Games. “We’re excited to see gamers jump in and explore the wonderfully hand-crafted world of Monoth with their friends and family.”
Featuring the authentic voice actors of Mickey, Minnie, Donald, and Goofy, Disney Illusion Island brings everyone together. Whether playing solo or teaming with up to three friends in local co-op, players will perform high flying platforming feats, uncover secrets, and take on epic boss encounters. There is always something new to discover in the expansive world of Monoth as players uncover the mystery of the stolen Tomes.
“Disney Illusion Island has been an absolute career high for myself and the studio,” said Aj Grand-Scrutton, Creative Director/CEO, Dlala Studios. “We have absolutely loved bringing Mickey, Minnie, Donald and Goofy back in a brand-new 2D platforming adventure and we can’t wait for players to join us in the world of Monoth!”
Disney Illusion Island is now available for $39.99, exclusively for Nintendo Switch on the Nintendo eShop and at retail, beginning today.
For more information about Disney Illusion Island: www.disneyillusionisland.com
For more updates on Disney Illusion Island, please follow us on social below:
About Disney Consumer Products, Games, and Publishing
Consumer Products, Games and Publishing (CPGP) is the division of Disney Parks, Experiences, and Products (DPEP) that brings beloved brands and franchises into the daily lives of families and fans through products – from toys to t-shirts, apps, books, console games and more – and experiences that can be found around the world, including on the shopDisney e-commerce platform and at Disney Parks, as well as local and international retailers. The business is home to world-class teams of product, licensing and retail experts, artists and storytellers, and technologists who inspire imaginations around the world.
About Dlala Studios
Dlala Studios are the creators of Disney Illusion Island and Battletoads (2020). They have also provided work for multiple award-winning titles, such as Sea of Thieves. The Essex-based studio has earned a reputation as an industry leader in 2D animation and for their unique, humorous narrative. The studio celebrated their 10th anniversary in 2022, growing to nearly 40 full-time employees.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230728085491/en/
Contact information
MEDIA CONTACTS
Dylan Quintero
Communications Manager
DYLAN.QUINTERO@DISNEY.COM
Melissa Lee
Senior Specialist, Communications
MELISSA.Y.LEE@DISNEY.COM
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom